Epidermal Growth Factor Receptor Inhibiting 4-Aminoquinazolines as Promising Anticancer Agents: A Patent Review (2000-Present)

Cancer is now recognized as a major threat to global health and a notable cause of human mortality. Rapid cell multiplication abilities and the unchecked cell expansion that develops from a single cell define it. The epidermal growth factor receptor is a member of the ERBB family of receptors (ERBB-1/2/3/4), and cancer can occur due to EGFR mutations. A lot of research is now being done on 4-aminoquinazolines to suppress EGFR. With FDA-approved medications based on the 4-aminoquinazoline core already in use, we think that this core holds a lot of promise for a novel type of cancer therapy with significant therapeutic benefits. In this patent review, we have surveyed a huge number of patents reported (2000-present) involving 4-aminoquinazoline core as an anticancer agent targeting EGFR. We attempt here, with a huge body of literature based on this core, to update researchers about the latest EGFR-targeted developments utilizing 4-aminoquinazolines, which will provide support for the development of novel kinase-targeted cancer therapies.

Automated summary

Cancer is recognized as a major global health threat and a leading cause of human mortality due to uncontrolled cell expansion. EGFR mutations play a role in cancer development and research is being done on 4-aminoquinazolines to suppress EGFR. This patent review aims to update researchers on the latest EGFR-targeted developments using 4-aminoquinazolines, which hold promise for novel kinase-targeted cancer therapies.